InMed Pharmaceuticals

INM · NASDAQ

$1.44+$0.11 (+8.27%)TodayMarket closed ·
Prev close $1.33

Latest news

  • NewsVandana Singh

    InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

  • Press releasePRNewswire

    Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

  • Press releasePRNewswire

    Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN

  • Press releasePRNewswire

    Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?

  • Press releaseNewsfile

    InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

  • Press releasePRNewswire

    Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • NewsAvi Kapoor

    Gold Falls 1%; Amer Sports Earnings Top Views

  • Press releaseBusiness Wire

    INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

  • NewsAvi Kapoor

    Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings

  • NewsVandana Singh

    Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline

  • News

    InMed Pharmaceuticals To Merge With Mentari Therapeutics

  • Press releasePRNewswire

    InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

  • Press releasePRNewswire

    /C O R R E C T I O N -- InMed Pharmaceuticals/

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • NewsAvi Kapoor

    Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

  • Press releaseNewsfile

    InMed Pharmaceuticals Amends Preferred Investment Options

  • News

    InMed Reports Preclinical Data Showing Reduced Brain Inflammation in Alzheimer's Models

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    InMed Pharmaceuticals Expects Negative Impact On BayMedica From New Act H.R. 5371; Says BayMedica Evaluating Alternative Supply Chain Options

  • NewsAvi Kapoor

    Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

  • NewsMohd Haider

    What's Driving InMed's (INM) 22% After-Hours Surge?

  • Press releaseGlobe Newswire

    InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

  • NewsMohd Haider

    Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data

  • Press releaseNewsfile

    InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

  • Press releaseNewsfile

    InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  • NewsVandana Singh

    Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge

  • News

    Market-Moving News for June 24th

  • Press releaseNewsfile

    InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

  • NewsAvi Kapoor

    Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

  • NewsAvi Kapoor

    Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Crude Oil Down 2%; D.R. Horton Earnings Top Views

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.